Dravet syndrome (DS) is one of the most severe childhood-onset epileptic encephalopathies. We have previously reported that adult patients with DS present a very peculiar motor phenotype with levodopa-responsive early onset parkinsonian features. 1 This initial observation raised two important questions: (1) are the motor features a consequence of the severe SCN1A gene mutation leading to DS phenotype, or are they simply a consequence of many years of severe seizures and large doses of combined antiepileptic treatment; and (2) does the adult motor phenotype help differentiate DS from Lennox-Gastaut syndrome (LGS), the other extremely severe pediatric-onset epileptic encephalopathy? In fact, LGS and DS patients share similar features, most notably having several types of seizures that are resistant to multiple antiepileptic drugs and associated with moderate to severe intellectual disability as well as autistic features.
To address the two preceding questions we carefully studied 14 adult patients with LGS and 14 with DS.
Methods
This study was approved by the University Health Network research ethics board, and informed consent was obtained from the patients' parents. Adult subjects were recruited from the Epilepsy Genetics Program at Toronto Western Hospital between July 2014 and March 2016.
Clinical assessment
Clinical data, electroencephalography (EEG) recordings, imaging reports, and seizure diaries were collected retrospectively from electronic and physical charts. Pediatric data were available for most patients, since they were evaluated as children in our affiliated pediatric hospital, The Hospital for Sick Children. Clinical variables assessed included demographics, seizure frequency, antiepileptic drugs (AEDs) used over the course of the disease, and complete neurologic examination. All the patients were examined by two adult neurologists with expertise in epilepsy (DA) or movement disorders (AF). The movement disorder specialist reevaluated 12 DS patients who were described previously, 1 as well as two new DS cases and 14 LGS patients. Exposure to antipsychotic drugs was an exclusion criterion.
Patients were evaluated using a modified Unified Parkinson's Disease Rating Scale (mUPDRS) (score of 0-76, with higher values indicating a more severe parkinsonism). 1 Antecollis and camptocormia were defined as forward flexion of the head or trunk, respectively, >45 degrees. 2 All patients had undergone genetic testing in the form of epilepsy gene panels including 470 genes associated with epilepsy (including SCN1A deletions/duplications)), as well as genome-wide chromosome microarray analysis. None of the patients in the LGS group had mutations in genes associated with DS. Only patients with pathologic SCN1A mutations were included in the DS group.
Statistical analysis
Differences in the distribution of categorical variables among groups were assessed with the chi-square test. Given the small number of participants in each group, continuous variables were compared with a nonparametric test (MannWhitney test). Statistical significance was accepted at pvalue <0.05.
Results
Adult patients with severe and intractable epilepsy, intellectual disability, childhood EEG recordings showing slow spike and wave discharges and generalized paroxysmal fast activity during sleep, and with no genetic abnormalities previously linked to DS were diagnosed (or had their diagnosis confirmed) as LGS. Patients with severe, intractable epilepsy, history of febrile seizures, intellectual disability, and pathologic SCN1A mutations were diagnosed with DS.
There was no significant difference in patient's age and gender. The neurologic examination results are shown in Table 1 . Antecollis was present in 9 of 14 DS and one of 14 LGS patients (p = 0.004) (Fig. 1) . Parkinsonian gait was present in 8 of 14 DS and one of 14 LGS patients (p = 0.012). There was no significant between-group difference in the severity of other parkinsonism features evaluated with mUPDRS and in the distribution of spasticity, cogwheel rigidity, and cerebellar gait.
Discussion
This study showed significant differences in the adult motor phenotype of patients with LGS and DS caused by SCN1A pathologic mutations. We have recently described a specific phenotype in a group of DS adults characterized by antecollis, parkinsonian gait, and other parkinsonian features. Of interest, treatment with levodopa improved the global bradykinesia and the asymmetric rigidity, and one of the patients no longer needed her wheelchair for longer walks.
1,2 However, it was not clear if those findings were (1) a consequence of years of intractable epilepsy damaging a developing brain and/or (2) the result of prolonged use of high doses of AEDs, and/or (3) associated with severe pathologic mutations in the SCN1A gene. To disentangle this issue, we chose to compare DS patients with LGS patients, who also had intractable epilepsy from a young age and were exposed to approximately the same types and doses of AEDs. The findings of this study suggest that the abnormal motor signs of antecollis and parkinsonian gait displayed by DS patients may be caused by the SCN1A mutation and are not simply a consequence of frequent seizures or AEDs use. Because SCN1A gene is also expressed in the basal ganglia, 3 it is possible that the severe SCN1A mutations leading to DS may also alter basal ganglia neuronal functioning, thereby leading to these parkinsonian features.
The findings of this study also help differentiate adult patients with DS from those with LGS. Dravet syndrome was described for the first time in French in 1978. 4 Many patients with DS born in the 1970s and 1980s did not have a proper diagnosis, since the condition was not widely known then as it is today. Unfortunately, many of these patients with DS carry to this date an improper diagnosis of LGS, despite the clinical differences between these two diseases (age of onset, sensitivity to fever, and predominance of different types of seizures at different stages of the disease). However, it is important to remember that these differences are lost as the syndromes progress and as the patients age. For instance, as the disease evolves, DS patients have less frequent status epilepticus, less prominent myoclonus, and overall fewer seizures. 5, 6 Regarding patients with LGS, only a minority of their EEG recordings in adult life display slow spike and wave complexes or paroxysmal fast activity, which are the hallmarks of LGS in childhood. 6 All these changes pose a problem to the adult neurologist, since often patients or their parents do not have proper documentation of seizures during childhood, and by the time these patients move to the adult health care system their parents can no longer remember the details of the childhood seizures after some of them have been replaced by other seizure types. 7 Making the correct diagnosis in adults with epileptic encephalopathies, or what used to be called "symptomatic epilepsy," is important for therapeutic and genetic counseling purposes. 8, 9 For example, AEDs blocking sodium channels usually worsen seizures in DS and, therefore, should be avoided. 10 Orphan drugs such as stiripentol can improve seizure control in DS. 11, 12 Genetic testing is an important, but still imperfect, tool for determining diagnosis in every patient. For instance, LGS is an etiologically variable condition, and to date few genes have been linked to it. 13, 14 Our study has limitations, the main one being that most of DS patients were evaluated in our earlier study defining the presence of the motor features. 1 In addition, we selected only those DS patients carrying SCN1A mutations; these represent approximately 80% of cases clinically diagnosed with DS. Therefore, our findings cannot be generalized to the whole population of DS patients or to the spectrum of milder epilepsy syndromes caused by SCN1A mutations. Finally, our sample is small, although it is large enough to detect a very significant difference between groups.
In conclusion, it can be difficult to distinguish DS from LGS in adulthood. We believe that the motor features of antecollis and parkinsonian gait in DS can help differentiate the diagnosis of DS or LGS in adults. This could help personalize the treatment, which may improve the patient's quality of life through better seizure and motor management, even after several years of pharmacoresistance. The other important conclusion of this study is that severe SCN1A mutations are likely associated with early onset parkinsonian gait and antecollis. 
